These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 36555268

  • 1. Association of BRAFV600E Mutation with the Aggressive Behavior of Papillary Thyroid Microcarcinoma: A Meta-Analysis of 33 Studies.
    Attia AS, Hussein M, Issa PP, Elnahla A, Farhoud A, Magazine BM, Youssef MR, Aboueisha M, Shama M, Toraih E, Kandil E.
    Int J Mol Sci; 2022 Dec 09; 23(24):. PubMed ID: 36555268
    [Abstract] [Full Text] [Related]

  • 2. BRAF V600E mutation in papillary thyroid microcarcinoma: is it a predictor for the prognosis of patients with intermediate to high recurrence risk?
    Cao J, Chen B, Zhu X, Sun Y, Li X, Zhang W, Wang X.
    Endocrine; 2024 Apr 09; 84(1):160-170. PubMed ID: 37851243
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, Qin HD, Liu SY.
    Zhonghua Zhong Liu Za Zhi; 2017 May 23; 39(5):361-366. PubMed ID: 28535653
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
    Silver JA, Bogatchenko M, Pusztaszeri M, Forest VI, Hier MP, Yang JW, Tamilia M, Payne RJ.
    J Otolaryngol Head Neck Surg; 2021 Nov 06; 50(1):63. PubMed ID: 34742355
    [Abstract] [Full Text] [Related]

  • 7. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
    Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, Kim SW, Lee EN, Hong JC.
    World J Surg Oncol; 2013 Nov 14; 11():291. PubMed ID: 24228637
    [Abstract] [Full Text] [Related]

  • 8. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
    Ma YJ, Deng XL, Li HQ.
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug 14; 35(4):591-599. PubMed ID: 26223933
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C, Guo Y, Lv Y, Nanding A, Shi T, Qin H, He J.
    PLoS One; 2016 Aug 14; 11(12):e0167414. PubMed ID: 27936049
    [Abstract] [Full Text] [Related]

  • 11. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
    Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M, Qu S.
    Endocr Relat Cancer; 2015 Apr 14; 22(2):159-68. PubMed ID: 25593071
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
    Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W.
    Ann Surg Oncol; 2009 Feb 14; 16(2):240-5. PubMed ID: 19034577
    [Abstract] [Full Text] [Related]

  • 15. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
    Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM.
    Ann Surg Oncol; 2010 Dec 14; 17(12):3294-300. PubMed ID: 20953721
    [Abstract] [Full Text] [Related]

  • 16. A Significance of Concomitant BRAFV600E and TERT Mutations in Polish Patients with Papillary Thyroid Microcarcinoma: A Retrospective Cohort Study Based on 430 Cases.
    Kuchareczko A, Kopczyński J, Kowalik A, Hińcza-Nowak K, Walczyk A, Pałyga I, Trybek T, Szymonek M, Gąsior-Perczak D, Gadawska-Juszczyk K, Mikina E, Płachta I, Suligowska A, Płusa A, Chrapek M, Łopatyński T, Góźdź S, Kowalska A.
    Thyroid; 2022 Nov 14; 32(11):1372-1381. PubMed ID: 35950639
    [Abstract] [Full Text] [Related]

  • 17. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C, Chen T, Liu Z.
    World J Surg Oncol; 2016 Sep 06; 14(1):241. PubMed ID: 27600854
    [Abstract] [Full Text] [Related]

  • 18. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
    Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M.
    Medicine (Baltimore); 2012 Sep 06; 91(5):274-286. PubMed ID: 22932786
    [Abstract] [Full Text] [Related]

  • 19. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
    Zhang Q, Liu SZ, Zhang Q, Guan YX, Chen QJ, Zhu QY.
    Cell Physiol Biochem; 2016 Sep 06; 38(2):763-76. PubMed ID: 26871894
    [Abstract] [Full Text] [Related]

  • 20. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF V600EDetection and Invasive Pathological Features of Papillary Thyroid Cancer].
    Zhang Y, Luo YK, Zhang Y, Zhang MB, Guang Y, Xie F, Jiang B, Tang J.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug 30; 41(4):517-523. PubMed ID: 31484615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.